KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $944.7 million.

  • Alnylam Pharmaceuticals' Non-Current Assets rose 5.80% to $898.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $898.9 million, marking a year-over-year increase of 5.80%. This contributed to the annual value of $944.7 million for FY2024, which is 11.51% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Non-Current Assets stood at $944.7 million for FY2024, which was up 11.51% from $847.2 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Non-Current Assets registered a high of $944.7 million during FY2024, and its lowest value of $792.3 million during FY2020.
  • For the 3-year period, Alnylam Pharmaceuticals' Non-Current Assets averaged around $882.0 million, with its median value being $854.1 million (2022).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Non-Current Assets increased by 16.64% in 2020, and later declined by 0.81% in 2023.
  • Alnylam Pharmaceuticals' Non-Current Assets (Yearly) stood at $792.3 million in 2020, then increased by 5.36% to $834.7 million in 2021, then grew by 2.32% to $854.1 million in 2022, then dropped by 0.81% to $847.2 million in 2023, then grew by 11.51% to $944.7 million in 2024.